Page last updated: 2024-12-07

sulfamethoxazole hydroxylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulfamethoxazole hydroxylamine : A sulfonamide compound having a 4-hydroxylaminophenyl group attached to the sulfur atom and a 1,2-oxazol-3-yl group attached to the nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID114821
CHEMBL ID1972802
CHEBI ID53016
MeSH IDM0166434

Synonyms (33)

Synonym
NCI60_022622
nsc-665547
hydroxylamine of sulfamethoxazole [3-(4-hydroxylamino phenylsulfonamido)-5-methylisoxazole]
sulfamethoxazole hydroxylamine
sulphamethoxazole hydroxylamine
smx-ha
benzenesulfonamide, 4-(hydroxyamino)-n-(5-methyl-3-isoxazolyl)-
4-(hydroxyamino)-n-(5-methylisoxazol-3-yl)benzenesulfonamide
114438-33-4
nsc665547
hydroxylamine of sulfamethoxazole
3-(4-hydroxylamino phenylsulfonamido)-5-methylisoxazole
smx-nhoh
4-(hydroxyamino)-n-(5-methyl-3-isoxazolyl)benzenesulfonamide
CHEBI:53016 ,
n-hydroxy sulfamethoxazole
sulfamethoxazole n4-hydroxylamine
4-(hydroxyamino)-n-(5-methyl-3-isoxazolyl)-benzenesulfonamide
4-(hydroxyamino)-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
AKOS005266663
s4yf7g89mz ,
unii-s4yf7g89mz
nsc 665547
FT-0670133
EPITOPE ID:115000
CHEMBL1972802
DTXSID00150731
J-003092
sulfamethoxazole hydroxylamine, analytical standard
mfcd00870463
hydroxylamine-smx
Q27123888
4-(hydroxyamino)-n-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Using sulfamethoxazole hydroxylamine (SMX-HA) as a model compound, we report the use of a pH-sensitive fluorescent probe, 2',7'-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF), to identify early subcellular targets of chemically synthesized, toxic drug metabolites in peripheral blood mononuclear cells."( Cellular toxicity of sulfamethoxazole reactive metabolites--I. Inhibition of intracellular esterase activity prior to cell death.
Dosch, HM; Leeder, JS; Spielberg, SP, 1991
)
0.74
" SMX-HA was toxic to isolated MNL from mixed breed dogs (MBD) and Doberman Pinschers."( An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs.
Cribb, AE; Spielberg, SP, 1990
)
0.28
"It has been suggested that the high rates of adverse reactions to sulfonamides among patients with AIDS may be related to an increased sensitivity to reactive drug metabolites among HIV-infected cells."( Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells.
Bird, IA; Dekaban, GA; Krause, R; Rieder, MJ, 1995
)
0.29
"Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions."( Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole.
Hess, DA; Madrenas, J; Puvanesasingham, R; Rieder, MJ; Sisson, ME; Suria, H; Wijsman, J, 1999
)
0.3
"Hypersensitivity adverse drug reactions are much more common among patients with acquired immunodeficiency syndrome (AIDS) than in the general population."( Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: influence of HIV infection on clindamycin toxicity in vitro.
Dekaban, GA; Rieder, MJ; Wijsman, JA, 2005
)
0.33
"Drug hypersensitivity reactions (DHRs) are rare but potentially fatal adverse drug reactions (ADRs)."( The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides.
Elzagallaai, AA; Koren, G; Rieder, MJ, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
isoxazolesOxazoles in which the N and O atoms are adjacent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1314011Drug level assessed as Staphylococcus saprophyticus ATCC 15305 nitroreductase B mediated compound formation using 130 uM NO2-SMX measured after 200 mins in presence of NADPH-cofactor generating system by LC-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID1314007Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 assessed as zone of inhibition at 54 ug/disc measured after 16 to 24 hrs by agar diffusion method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID1314009Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 measured after 18 hrs by broth dilution method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.27)18.7374
1990's17 (38.64)18.2507
2000's17 (38.64)29.6817
2010's8 (18.18)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.91 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index5.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (13.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]